GlassScriptPhysician profile
Timothy Carpenter
NPI 1215008297
$3,311.63
in general payments reported to CMS, 2019-2025
16 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $290 · 2022: $40.42 · 2023: $1,524 · 2024: $387 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663 · Travel and Lodging: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.74 |
| Travel and Lodging | $776.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,306.98 | 2023 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $520.55 | 2019-2020 | |
| Alkermes, INC. | $347.04 | 2019-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $202.03 | 2022-2025 | Sublocade |
| Braeburn INC. | $193.69 | 2023-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $172.54 | 2019-2024 | Spravato, Invega Trinza, Invega Sustenna |
| Axsome Therapeutics, INC. | $156.52 | 2025 | Auvelity |
| Uswm, LLC | $141.10 | 2023 | Zimhi, Lucemyra |
| Jazz Pharmaceuticals INC. | $59.50 | 2019 | |
| Abbvie INC. | $53.07 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $39.66 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.72 | 2020-2025 | Caplyta |
| Shire North American Group INC | $29.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.58 | 2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2024 | Abilify Maintena |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $17.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.